Replies to post #58807 on Anavex Life Sciences Corp (AVXL)

[blanka]

CORRECT!!!

A3-71 Getting Orphan Status means FDA believes Anavex has First in Class Drug for CNS Diseases. PERIOD.

All else is smoke and mirrors...


AVXL

[Amatuer17]

All CNS diseases have the big problem of BBB - this limits the number of molecules that can really treat CNS - as such all pharma stick to same molecule once they find that it can overcome BBB and then comes non- toxicity and then comes efficacy.

A2-73 has crossed the BBB hurdle and toxicity which is big news - now we are looking at efficacy.
If 3-71 proves that it can cross BBB hurdle - AVXL will have 2 potent compounds on hand and right scientific minds can do some wonders - so I personally think the risk-reward in this case is highly tilted to rewards (all biotechs have high risk until proven successful)


http://www.ncbi.nlm.nih.gov/pmc/articles/PMC539316/


"Summary: The blood-brain barrier (BBB) is formed by the brain capillary endothelium and excludes from the brain ~100% of large-molecule neurotherapeutics and more than 98% of all small-molecule drugs. Despite the importance of the BBB to the neurotherapeutics mission, the BBB receives insufficient attention in either academic neuroscience or industry programs. ..."